研究
教育
解決策
サインイン
JA
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Turkish
JA - Japanese
Vicki G. Davis has not added Biography.
If you are Vicki G. Davis and would like to personalize this page please email our Author Liaison for assistance.
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.
Schizophrenia research Apr, 2008 | Pubmed ID: 18258416
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.
Schizophrenia research Aug, 2008 | Pubmed ID: 18534821
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.
Schizophrenia research Oct, 2008 | Pubmed ID: 18775645
Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial.
Schizophrenia research Aug, 2009 | Pubmed ID: 19545976
Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.
Biological psychiatry Dec, 2009 | Pubmed ID: 19640511
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
The Journal of clinical psychiatry Mar, 2011 | Pubmed ID: 20816031
NeuroCog Trials, Inc.
Stacy A. Ruse1,
Vicki G. Davis1,
Alexandra S. Atkins1,
K. Ranga R. Krishnan2,3,
Kolleen H. Fox4,
Philip D. Harvey5,
Richard S.E. Keefe1,3
1, NeuroCog Trials, Inc.,
2, Duke-NUS Graduate Medical Center,
3, Duke University Medical Center,
4, Fox Evaluation and Consulting, PLLC,
5, University of Miami Miller School of Medicine
個人情報保護方針
利用規約
一般データ保護規則
お問い合わせ
図書館への推薦
JoVE ニュースレター
JoVE Journal
メソッドコレクション
JoVE Encyclopedia of Experiments
アーカイブ
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
教員向けリソースセンター
著者
図書館員
アクセス
JoVEについて
Copyright © 2023 MyJoVE Corporation. All rights reserved
